gemcitabine

P1/2, N=122, Recruiting, Oncolytics Biotech

Gemcitabine/Cisplatin (Gem/Cis) chemotherapy is a standard treatment for muscle-invasive bladder cancer (MIBC) but yields suboptimal response rates. Using TCGA bladder cancer data, the transcriptomic gene set was further validated revealing a prognostic signature associated with patients' outcome. These findings uncover a novel mechanism of chemotherapy resistance in bladder cancer driven by tumor-stromal interactions and macrophage recruitment and suggest that targeting macrophage infiltration may improve chemotherapy response in bladder cancer.

P1/2, N=314, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

P1, N=15, Active, not recruiting, South Metropolitan Health Service | Recruiting --> Active, not recruiting

P3, N=501, Active, not recruiting, Revolution Medicines, Inc. | Recruiting --> Active, not recruiting

Paclitaxel, gemcitabine, and cisplatin (all p < 0.05) may be more useful in EC patients with high expression of targeted srlncRNAs in the GDSC database. The EC-18 PDO was more resistant to three drugs, which aligned with clinical observation. The srlncRNA signature (AL121906.2, AP002761.4, BX322234.1, LINC00662, LINC00908, VIM-AS1, and ZNF236-DT) could guide prognosis prediction and treatment choices for EC patients.

Treatment with gemcitabine and oxaliplatin chemotherapy showed significant improvement, complemented by radiotherapy for refractory lesions. Histopathological evaluation and EBV testing are critical for differentiation from other conditions. While initial responses to chemoradiotherapy are promising, recurrence remains common, highlighting the need for vigilant follow-up and optimized therapeutic strategies.

P2, N=156, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting

P1/2, N=183, Recruiting, Tango Therapeutics, Inc. | N=133 --> 183

Upregulation of STEAP3 suppresses ferroptosis by increasing glutathione levels and reducing lipid peroxidation, ultimately promoting tumor proliferation and gemcitabine resistance. Our study identifies the USP10-IGF2BP3-STEAP3 axis as a critical mechanism underlying chemoresistance in pancreatic cancer, suggesting that targeting USP10 may offer a promising therapeutic strategy for overcoming gemcitabine resistance.

LBL-007 plus tislelizumab and chemotherapy shows promising clinical benefits and manageable toxicity as first-line therapy for RM-NPC. Dual-positive LAG-3/PD-L1 expression was associated with improved outcomes, supporting further exploration of this biomarker-defined subpopulation in randomized trials.